SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Metabasis Therapeutics , announced today that the Company will present at two investor conferences in New York, NY in early November. A business overview and a discussion of the Company's product candidates in clinical and pre-clinical development are expected to be provided at both conferences.
Rodman & Renshaw 8th Annual Healthcare Conference
Dr. Paul Laikind, president and chief executive officer is scheduled to present on November 6, 2006 at 8:50 a.m. Eastern Time during the Rodman & Renshaw 8th Annual Healthcare Conference at The New York Palace Hotel.
CIBC World Markets 17th Annual Healthcare Conference
Mr. John Beck, senior vice president of finance and chief financial officer is scheduled to present on November 6, 2006 at 3:15 p.m. Eastern Time during the CIBC World Markets 17th Annual Healthcare Conference at the Waldorf-Astoria Hotel.
To access the live audio broadcasts and the subsequent archived audio recordings of both presentations, please log onto the Company's website at www.mbasis.com under the "Investors" section. The audio recordings will be archived there for 30 days following the live presentations. Please connect to Metabasis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of novel drugs to address some of the world's most widespread and costly chronic diseases involving pathways in the liver. The Company has established a pipeline that includes clinical stage and preclinical product candidates targeting major diseases with significant unmet medical needs. Targeted diseases include major metabolic diseases such as diabetes, hyperlipidemia and obesity as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.
Metabasis TherapeuticsCONTACT: Constance Bienfait, Vice President, Investor Relations &Corporate Communications of Metabasis Therapeutics, Inc., +1-858-622-5575
Web site: http://www.mbasis.com/
